[{"id":"3a03b175-0fe2-4a87-abd3-94e44f7e3cc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04260802","created_at":"2021-01-18T20:42:20.349Z","updated_at":"2024-07-02T16:35:27.907Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","source_id_and_acronym":"NCT04260802","lead_sponsor":"Ocellaris Pharma, Inc.","biomarkers":" HER-2 • ER • ALK • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion","tags":["HER-2 • ER • ALK • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OC-001"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/06/2020","start_date":" 10/06/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2023-11-28"}]